AION实验室与BioMed X持续合作，启动2025年全球应用征集：用于新靶点组合的生成式人工智能-动脉网

AION Labs, In Continued Partnership with BioMed X, Launches 2025 Global Call for Applications: Generative AI for Novel Target Combinations

CISION 等信源发布 2025-03-04 21:00



可切换为仅中文







Israel-Based Venture Studio Comprising AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund, Amiti Ventures and Amazon Web Services (AWS)

由阿斯利康、默克、辉瑞、梯瓦、以色列生物技术基金、阿米蒂风险投资和亚马逊网络服务（AWS）组成的以色列风险工作室

Seeks Global Research and Technology Talent to Form New Startup Focused on: '

寻求全球研发和技术人才，组建新创业公司，专注于：'

Generative AI for Novel Target Combinations'

生成式人工智能用于新目标组合

REHOVOT,

雷霍沃特，

Israel

以色列

and HEIDELBERG,

和海德堡，

Germany

德国

，

March 3, 2025

2025年3月3日

/PRNewswire/ --

AION Labs

AION实验室

, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and German independent research institute

，首家推动采用人工智能技术和计算科学解决治疗挑战的风险工作室，以及德国独立研究机构

BioMed X

, announced today the launch of its latest global call for applications to identify scientific founders: computational biologists, biomedical scientists, and AI experts to form a new startup at AION Labs' headquarters in Rehovot,

今天宣布启动其最新的全球招募活动，以寻找科学创始人：计算生物学家、生物医学科学家和人工智能专家，共同在 AION 实验室位于雷霍沃特的总部成立一家新创业公司，

Israel

以色列

。

AION Labs' next startup will focus on developing an AI-driven computational platform to systematically identify, rank, and validate molecular target combinations for multispecific biologic drugs. Multi-functional drug modalities, such as bispecific antibodies and multispecific peptides, have demonstrated potential clinical success in treating complex diseases like cancer and metabolic disorders, with hundreds currently in development.

AION Labs的下一个初创公司将专注于开发一个AI驱动的计算平台，以系统地识别、排序和验证多特异性生物药物的分子靶标组合。多功能药物模式，如双特异性抗体和多特异性肽，已在治疗癌症和代谢紊乱等复杂疾病方面展现出潜在的临床成功，目前有数百种此类药物正在开发中。

However, designing these drugs requires moving beyond single-target approaches toward multi-target molecular discovery..

然而，设计这些药物需要超越单一目标的方法，朝着多目标分子发现的方向发展。

Traditional target discovery relies on expert-driven hypotheses, literature reviews, academic research, and fragmented experimental data, all generated on a single target with a single drug. The aim of the new AI-driven platform will be to prioritize novel combinations based on disease relevance, biomarker predictability, and on-target adverse reaction risks in therapeutic areas such as oncology, cardiovascular-kidney-metabolic (CKM) diseases, and immune-mediated disorders.

传统靶点发现依赖于专家驱动的假设、文献综述、学术研究和针对单一靶点与单一药物的碎片化实验数据。新的AI驱动平台的目标将是基于疾病相关性、生物标志物可预测性以及在肿瘤学、心血管-肾脏-代谢（CKM）疾病和免疫介导疾病等治疗领域中的靶向不良反应风险，优先考虑新型组合。

The technology developed by the startup will be tested and validated under the guidance of AION Labs' pharmaceutical partners..

这家初创公司开发的技术将在 AION Labs 的制药合作伙伴的指导下进行测试和验证。

The integration of AI in multi-target drug discovery has the potential to revolutionize the identification of new therapeutic strategies. By systematically analyzing large-scale biomedical data, AI can uncover intricate molecular interactions and propose optimized target combinations that may have been overlooked through traditional methods.

人工智能在多靶点药物发现中的整合有可能彻底改变新治疗策略的识别。通过系统分析大规模生物医学数据，人工智能可以揭示复杂的分子相互作用，并提出可能被传统方法忽视的优化靶点组合。

This computationally driven approach may enhance .

这种计算驱动的方法可能会增强。

the

discovery process, enabling development of biologics tailored to specific disease mechanisms while potentially reducing the risk of off-target adverse effects.

发现过程，能够开发针对特定疾病机制的生物制剂，同时可能降低脱靶不良反应的风险。

'AI is transforming biologic drug design, enabling the discovery of drugs that modulate multiple proteins simultaneously. To fully harness this progress, we must identify the right target combinations for multispecific biologics,' said

“人工智能正在变革生物药物设计，使得同时调节多个蛋白质的药物发现成为可能。为了充分利用这一进展，我们必须确定多特异性生物制剂的正确靶点组合，”

Dr.

博士

Yair Benita

雅伊尔·贝尼塔

, CTO of AION Labs

AION Labs的首席技术官

. 'By integrating advanced computational approaches with deep industry expertise, we believe this initiative has the potential to enhance the discovery cycle of therapeutic targets and their corresponding drugs, paving the way for novel strategies to address complex diseases.'

“通过将先进的计算方法与深厚的行业专业知识相结合，我们相信这一举措有潜力加强治疗靶点及其相应药物的发现周期，为解决复杂疾病开辟新策略。”

AION Labs is inviting global entrepreneurs, computational biologists, bioinformatics scientists, AI and machine learning professionals, and experts in target identification or disease biology combination pathways to submit a proposal addressing the challenge.

AION实验室正在邀请全球企业家、计算生物学家、生物信息学科学家、人工智能和机器学习专业人士，以及在靶点识别或疾病生物学组合通路方面的专家提交应对该挑战的提案。

Original ideas that surpass the current state-of-the-art are particularly encouraged.

特别鼓励超越当前最先进技术的原创想法。

As part of the online application procedure, interested candidates are requested to submit an initial project proposal via the BioMed X Career Space at

作为在线申请程序的一部分，感兴趣的候选人需通过BioMed X职业空间提交初步项目提案。

https://career.bio.mx/call/2025-AIL-C08

before

之前

May 05, 2025

2025年5月5日

。

Further details about this call for applications can be found on the AION Labs website:

可在AION实验室网站上找到有关此申请征集的更多详细信息：

www.aionlabs.com

。

About AION Labs

关于AION实验室

AION Labs is a first-of-its-kind venture studio comprising

AION Labs 是一家首创的风险工作室，包含

AstraZeneca

阿斯利康

，

Merck

默克集团

，

Pfizer

辉瑞

，

Teva

特瓦

, the

，这个

Israel Biotech Fund

以色列生物技术基金

，

Amiti Ventures

, and

，以及

Amazon Web Services (AWS)

亚马逊网络服务（AWS）

, powered by

，由...提供支持

BioMed X

生物医学X

with the support of the Israeli Government via the

在以色列政府通过 the 的支持下

Israel Innovation Authority

以色列创新局

, that have come together with one clear mission: to create and adopt groundbreaking new AI technologies that will transform the process of drug discovery and development in order to contribute to the health and well-being of all people world-wide.

，这些机构为了一个明确的使命走到一起：创造和采用突破性的全新AI技术，以改变药物发现和开发的过程，从而为全世界人民的健康和福祉做出贡献。

AION Labs is a unique venture hub where brilliant innovators and scientist-founders convene from around the world to solve the biggest R&D challenges guided by years of accumulated know-how, data and experience in pharma. The lab leverages its partners' wealth of knowledge and a new multidisciplinary mindset with the ingenuity, agility and innovative power of Israel's start-up ecosystem, to develop strong companies with clear long-term strategies, that will pave the way to the future of healthcare.

AION Labs是一个独特的创新中心，来自世界各地的杰出创新者和科学家创始人汇聚于此，依托多年积累的制药行业知识、数据和经验，解决最大的研发挑战。该实验室利用其合作伙伴的丰富知识和跨学科的新思维模式，结合以色列初创企业生态系统的创造力、敏捷性和创新力量，打造具有明确长期战略的强大公司，为医疗保健的未来铺平道路。

AION Labs cultivates innovation from within; its unique venture creation process bridges the gap between outstanding academic research in the field of AI and the biggest R&D needs in the discovery and development of new medicines for the benefit of patients. .

AION Labs从内部激发创新，其独特的风险创建流程弥合了人工智能领域杰出学术研究与患者新药发现和开发中最大研发需求之间的差距。

For more information, visit

欲了解更多信息，请访问

aionlabs.com

Follow AION Labs on

关注 AION Labs

领英

and

和

。

For media inquiries, contact Raoul Wootliff at

媒体咨询请联系Raoul Wootliff，邮箱：